January 19, 2018 / 10:36 PM / 5 months ago

BRIEF-Zealand Pharma Announces Progress To Phase 3 With Dasiglucagon For The Treatment Of Congenital Hyperinsulinism

Jan 19 (Reuters) - Zealand Pharma A/S:

* ZEALAND PHARMA ANNOUNCES PROGRESS TO PHASE 3 WITH DASIGLUCAGON FOR THE TREATMENT OF CONGENITAL HYPERINSULINISM IN FIRST HALF 2018

* ZEALAND PHARMA - U.S. FDA APPROVED ZEALAND’S INVESTIGATIONAL NEW DRUG APPLICATION FOR INITIATION OF TWO PHASE 3 CLINICAL TRIALS OF DASIGLUCAGON IN CHI​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below